INN Working Document 20.493
09/12/2020

Addendum[1] to
"The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" WHO/EMP/RHT/TSN/2018.1

Programme on International Nonproprietary Names (INN)

Health Products Policy and Standards (HPS)
Access to Medicines and Health Products (MHP)

World Health Organization, Geneva

Addendum[1] to "The use of stem s in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - WHO/EMP/RHT/TSN/2018.1

[1] This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of *"The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances"* 2018.

-adenant **adenosine receptors antagonists**

ciforadenant (118), inupadenant (123), preladenant (99), taminadenant (120), tozadenant (106), vipadenant (103)

-caftor **cystic fibrosis transmembrane regulator (CFTR) protein modulators, correctors, and amplifiers**

bamocaftor (121), deutivacaftor (118), dirocaftor (123), elexacaftor (121), galicaftor (119), icenticaftor (122), ivacaftor (104), lumacaftor (105), navocaftor (121), nesolicaftor (122), olacaftor (119), posenacaftor (122), tezacaftor (114)

-calcet/-calcet- **calcium-sensing receptors (CaSR) agonists**

cinacalcet (88), etelcalcetide (112), evocalcet (113), tecalcet (87), upacicalcet (118)

-cerfont **corticotropin-releasing factor (CRF) receptor antagonists**

crinecerfont (120), emicerfont (102), pexacerfont (97), tildacerfont (119), verucerfont (102)

-copan **complement receptor antagonists/ complement inhibitors**

avacopan (114), danicopan (119), iptacopan (122), nomacopan (119)

(c) category: pegcetacoplan (120), zilucoplan (118)

-corat **glucocorticoid receptor agonists**

dagrocorat (111), fosdagrocorat (111), mapracorat (102), tomicorat (108), velsecorat (121)

-espib **heat shock protein (HSP) 90 inhibitors (other than *–mycin*)**

icapamespib (123), ganetespib (105), luminespib (108), onalespib (112), pimitespib (121), zelavespib (123)

-fexor **farnesoid X receptor agonists**

cilofexor (119), nidufexor (118), tropifexor (116), turofexorate isopropyl (103), vonafexor (122)

-fusp **fusion proteins**[1]

bintrafusp alfa (121), cinrebafusp alfa (121), clervonafusp alfa (120), lorukafusp alfa (120), modakafusp alfa (122), onfekafusp alfa (118), oplunofusp (123), pabinafusp alfa (120), rozibafusp alfa (120), simlukafusp alfa (121), tagraxofusp (118), tebentafusp (118), valanafusp alfa (118)

-golix **gonadotropin releasing hormone (GnRH) antagonists**

elagolix (99), linzagolix (118), opigolix (118), relugolix (107), sufugolix (89)

-irine **cytotoxic pyrrolobenzodiazepine dimers and analogues**

camidanlumab tesirine (117), loncastuximab tesirine (117), mipasetamab uzoptirine (123), rolinsatamab talirine (119), rovalpituzumab tesirine (114), serclutamab talirine (120), tamrintamab pamozirine (120), vadastuximab talirine (113)

-ixafor **chemokine CXCR4 antagonists**

balixafortide (112), burixafor (104), mavorixafor (118), motixafortide (120), plerixafor (93)

[1] *A fusion protein is defined as a multifunctional protein derived from a single nucleotide sequence which may contain two or more genes or portions of genes with or without amino acid linker sequences. The genes should originally code for separate proteins, with at least two of them endowed with pharmacological action (e.g. action and targeting).* "Notes from the fusion protein Working Group", INN Working Document number 17.414 rev.

-ixibat **ileal bile acid transporter (IBAT) inhibitors, bile acid reabsorption inhibitors**

barixibat (88), elobixibat (104), linerixibat (118), maralixibat chloride (113), odevixibat (119), volixibat (113)

–leuton **5-lipo-oxygenase inhibitors, anti-inflammatory**

atreleuton (78), diroleuton (118), epeleuton (118), fenleuton (72), setileuton (101), zileuton (63)

---

stat enzyme inhibitors

-becestat **beta secretase inhibitors**

atabecestat (117), elenbecestat (117), umibecestat (119), lanabecestat (116), verubecestat (112)

-glustat **ceramide glucosyltransferase inhibitors**

duvoglustat (102), eliglustat (103), miglustat (85), sinbaglustat (121), venglustat (114)

-stinel ***N*-methly-D-aspartate (NMDA) receptor co-agonists**

apimostinel (115), gavestinel (77), licostinel (77), rapastinel (111), zelquistinel (121)

-tinib tyrosine kinase inhibitors

-ertinib **epidermal growth factor receptor (EGFR) inhibitors**

abivertinib (119), befotertinib (123), canertinib (87), epertinib (115), lazertinib (117), mavelertinib (118), mobocertinib (121), olafertinib (121), osimertinib (113), rezivertinib (122), xiliertinib (121), zorifertinib (121)

(b) category: ulixertinib (113), ravoxertinib (115) (Erk inhibitors)

(c) category: afatinib (104), olmutinib (114), erlotinib (85), gefitinib (85), mubritinib (90), nazartinib (114), mubritinib (90), nazartinib (114)

-tirom(-)	**antihyperlidaemic; thyromimetic derivatives**

acetiromate (30), axitirome (82), bentiromide (41), eprotirome (99), resmetirom (119), sobetirome (100)

-toclax	**B-cell lymphoma 2 (Bcl-2) inhibitors, antineoplastics**

obatoclax (94), navitoclax (103), venetoclax (111), imlatoclax (115), pelcitoclax (122), tapotoclax (121), mirzotamab clezutoclax (121), murizatoclax (122)

Amendments were also made in the following stems' definitions:

-imus
from *immunosuppressants, other than antineoplastics*
to *immunosuppressants, ~~other than antineoplastics~~*

-isant
from *histamine H_3 receptor antagonists*
to *histamine H_3 receptor antagonists, inverse agonists*

under *-tant*
-netant
from *neurokinin NK3 receptor antagonists*
to *neurokinin NK3 and dual NK3-NK1 receptor antagonists*

-pressin
from *vasoconstrictors, vasopressin derivatives*
to *~~vasoconstrictors,~~ vasopressin analogues*

-pride
from *sulpiride derivatives*
to *sulpiride derivatives and analogues*

-prim
from *antimicrobials, dihydrofolate reductase (DHFR) inhibitors, trimethoprim derivatives*
to *antimicrobials, dihydrofolate reductase (DHFR) inhibitors, trimethoprim ~~analogues~~*

-renone (new)
from *aldosterone receptor antagonists, spironolactone derivatives*
to *mineralocorticoid receptor (MR, MCR, aldosterone receptor) antagonists*

Amendments were also made in the stem's infix:

-gromab
from *-gro**s**mab*
for the designation of INN for monoclonal antibodies targeting skeletal muscle mass related growth factors and receptors